Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 16/20 | 0.51 |
| ▸ | PPARA | Q07869 | 15/20 | 0.51 |
| ▸ | PPARD | Q03181 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4030774 | 0.93 | FFAR1 (0.52) | FFAR1KDRPPARGPPARAPPARD | |
| SCHEMBL4025977 | 0.92 | PPARA (0.52) | FFAR1KDRPPARGPPARAMAPT | |
| SCHEMBL4026013 | 0.92 | FFAR1 (0.54) | FFAR1KDRPPARGPPARAMAPT | |
| SCHEMBL4028342 | 0.91 | PPARA (0.51) | FFAR1KDRPPARGPPARAMAPT | |
| SCHEMBL4026911 | 0.91 | FFAR1 (0.56) | FFAR1KDRPPARGPPARAMAPT | |
| SCHEMBL4027562 | 0.90 | FFAR1 (0.53) | FFAR1KDRPPARGPPARAMAPT | |
| SCHEMBL4026189 | 0.89 | FFAR1 (0.50) | FFAR1KDRPPARGPPARAMAPT | |
| SCHEMBL4027772 | 0.88 | FFAR1 (0.52) | FFAR1PPARGPPARAPPARD | |
| SCHEMBL4025872 | 0.87 | FFAR1 (0.50) | FFAR1KDRPPARGPPARAMAPT | |
| SCHEMBL4031984 | 0.87 | PPARG (0.51) | FFAR1KDRPPARGPPARAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569916-B1 | SUBSTITUTED ARALKYL DERIVATIVES | CADILA HEALTHCARE LTD (IN) | 2009-01-07 | — | — | EP | claimed |
| US-20060142277-A1 | Substituted aralkyl derivatives | CADILA HEALTHCARE LIMITED | 2006-06-29 | — | — | US | claimed |
| US-20090275565-A1 | Substituted aralkyl derivatives | CADILA HEALTHCARE LIMITED (IN) | 2009-11-05 | — | — | US | disclosed |
| EP-1569916-B1 | SUBSTITUTED ARALKYL DERIVATIVES | CADILA HEALTHCARE LTD (IN) | 2009-01-07 | — | — | EP | disclosed |
| US-20060142277-A1 | Substituted aralkyl derivatives | CADILA HEALTHCARE LIMITED | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142277-A1 | Substituted aralkyl derivatives | UGT1A7, UGT1A10, UGT2B7 | FFAR1 2147/4885KDR 1821/4885PPARG 2043/4885 |
| US-20090275565-A1 | Substituted aralkyl derivatives | UGT1A7, UGT1A10, UGT2B7 | FFAR1 2147/4885KDR 1821/4885PPARG 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.